Exact Sciences (NASDAQ:EXAS) vs. ANGLE (OTCMKTS:ANPCY) Head to Head Review

ANGLE (OTCMKTS:ANPCY) and Exact Sciences (NASDAQ:EXAS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Valuation and Earnings

This table compares ANGLE and Exact Sciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANGLE	N/A	N/A	N/A	C($0.48)	-2.42
Exact Sciences	$2.61 billion	4.96	-$204.15 million	($1.32)	-53.23

ANGLE has higher earnings, but lower revenue than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for ANGLE and Exact Sciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANGLE	0	0	0	0	N/A
Exact Sciences	0	1	14	0	2.93

Exact Sciences has a consensus target price of $78.38, suggesting a potential upside of 11.56%. Given Exact Sciences’ higher probable upside, analysts clearly believe Exact Sciences is more favorable than ANGLE.

Profitability

This table compares ANGLE and Exact Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ANGLE	N/A	N/A	N/A
Exact Sciences	-6.70%	-4.97%	-2.41%

Institutional and Insider Ownership

88.8% of Exact Sciences shares are held by institutional investors. 1.4% of Exact Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

About ANGLE

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company’s pipeline products focus on enhancing the Cologuard test’s performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.